

Introducing RNA Therapeutics 2017 – Agenda Released

SMI's 8th annual RNA Therapeutics conference will return to Central London on 22nd and 23rd February 2017 with an exclusive keynote from the MHRA

LONDON, ENGLAND, UNITED KINGDOM, October 3, 2016 /EINPresswire.com/ -- SMI's Group are delighted to announce the return of [RNA Therapeutics](#) set to take place next February in Central London. The agenda for 2017 will feature a mix of case study-led presentations, panel debates, interactive workshops and keynote addresses tailored for an audience of professionals and research scientists looking to develop and commercialise novel RNA therapeutics and delivery systems.

Now in its 8th year, RNA Therapeutics 2017 will showcase new developments through clinical and pre-clinical results in areas such as: messenger RNA-based therapeutics, anti-sense oligonucleotides and new sites for RNA silencing.

Event highlights will include topics on emerging concepts in nanoparticle delivery systems, small activating RNA and 3rd generation antisense technology. The conference will also hone in on under-met areas such as targeted delivery beyond the liver, and offer regulatory guidance on the reporting of clinical data through an exclusive MHRA keynote.



Pushing the boundaries of 21st century pharmaceuticals through targeted delivery systems

SMi Group

Featured speakers include:

- Nagy Habib, Head of Surgery, Co-Founder, Imperial College Healthcare NHS Trust, MiNA Therapeutics
- John Johnston, Clinical Assessor Biologicals &

Biotechnology Unit, MHRA

- Heinrich Haas, Vice President RNA Formulation & Drug Delivery, BioNTech RNA Pharmaceuticals
- Bo Rode Hansen, Global Head of RNA Therapeutics, Roche
- Nicole Meisner-Kober, Senior Investigator, RNA Biology, Novartis Institutes for Biomedical Research
- Steve Hood, Director, Bioimaging, GSK
- David Giljohann, CEO, Excicure
- Shai Erlich, Chief Medical Officer & President USA, Quark Pharmaceuticals Inc
- Amotz Shemi, CEO, Silenseed
- Sanyogitta Puri, Associate Principal Scientist, AstraZeneca



A detailed agenda and [full speaker line-up](#) is available at www.therapeutics-rna.com

--- end ---

Contact Information:

For all media enquiries contact Teri Arri on Tel: +44 (0)20 7827 6162 / Email: tarri@smi-online.co.uk
To register for the conference, visit www.pre-filled-syringes.com or contact Fateja Begum on
Tel: +44 (0)20 7827 6184 / Email: fbegum@smi-online.co.uk
To sponsor, speak or exhibit at the conference, contact Alia Malick on Tel: +44 (0)20 7827 6168 /
Email: amalick@smi-online.co.uk

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at <http://www.smi-online.co.uk>

Teri Arri
SMi Group
2078276000
[email us here](mailto:tarri@smi-online.co.uk)

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.
© 1995-2016 IPD Group, Inc. All Right Reserved.